Retina

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Management strategies for patients with ocular syphilis primarily involve antibiotic treatment achieved using high-dose intravenous or intramuscular penicillin.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

CRU Cofounder John Gelles, OD, gives his first impressions on how the conference is going thus far in Napa, California.

Researchers developed eye drop formulations 17-mer and H105A, both containing a short peptide, to administer to mice in the form of a drop on the eye’s surface.

The Retina Institute of Illinois is led by 9 physicians who have been providing comprehensive eye care in Illinois for almost 25 years.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

ENCELTO is the first and only FDA-approved treatment for MacTel.

Julie Rodman, OD, MS, FAAO, sits down with Optometry Times to discuss her anticipation for the future of technology in optometry, especially retinal care.

Ahead of her SECO presentations, Julie Rodman, OD, MS, FAAO, shares some tidbits of what attendees can expect.

The study examined changes in genes and proteins of the retinas of 9 strains of mice.

The study found that 17.4% of Medicare patients needed subspecialized procedures relative to 5.6% of surgeons practicing in rural areas between 2012 and 2022.

The agent class’s pleiotropic effects should keep optometrists vigilant.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

DRSS results remained stable or improved with OKT-TKI, and the drug was well-tolerated in the study.

The 3-year, $4.8 million award comes from the NIH Venture Program Oculomics Initiatives.

Preclinical studies evaluating NPI-001 have found that it boosts the endogenous antioxidant glutathione, which stops chemically aggressive oxygen molecules from further damaging retinal cells, according to Nacuity Pharmaceuticals.

Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.